<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672123</url>
  </required_header>
  <id_info>
    <org_study_id>GDF-15 APE</org_study_id>
    <nct_id>NCT03672123</nct_id>
  </id_info>
  <brief_title>GDF-15 Levels in Risk Stratification in Acute Pulmonary Embolism</brief_title>
  <official_title>GDF-15 Levels in Risk Stratification in Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational study evaluating serum GDF-15 levels in patients with acute
      pulmonary embolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective observational study evaluating serum GDF-15 levels in patients with acute
      pulmonary embolism (APE).

      In APE right ventricle failure developing due to ischemia and myocarditis is considered the
      primary cause of death, however, its pathomechanism has not been fully established yet.
      Growth differentiation factor 15 (GDF-15) is a chemokine secreted by activated macrophages in
      response to oxidative stress. It has now been shown that ischemic injury, mechanical stretch,
      and pro-inflammatory cytokines also stimulate the expression of GDF-15 in cardiac myocytes.
      The objective of this project is to describe the role of GDF-15 in the pathomechanism of
      acute right ventricle failure in the setting of acute pulmonary embolism and to verify the
      hypothesis that higher serum concentrations of GDF-15 are associated with more advanced right
      ventricle dysfunction and failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hemodynamic deterioration</measure>
    <time_frame>assessed daily through study completion, average of 10 days</time_frame>
    <description>Hemodynamic deterioration defined according to ESC criteria as:
change in blood pressure defined as: drop in systolic arterial blood pressure &lt; 90 mmHg or at least 40 mmHg, lasting â‰¤ than 15 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic complications</measure>
    <time_frame>assessed daily through study completion, average of 10 days</time_frame>
    <description>Major bleeding defined according to ISTH (International Society on Thrombosis and Haemostasis) criteria.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>APE with RVD</arm_group_label>
    <description>RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APE without RVD</arm_group_label>
    <description>RVD defined according to ESC criteria</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum/plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will recruit 270 patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with APE hospitalized who give written consent.

        Exclusion Criteria:

          -  lack of informed consent

          -  APE with symptoms lasting above 14 days before the admission

          -  acute coronary syndrome, diagnosed pulmonary hypertension

          -  severe valve disease

          -  sepsis

          -  active malignancy

          -  diagnosed mitochondrial diseases

          -  chronic kidney disease at least stage 4 (KDIGO)

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Z Skowronska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Pruszczyk, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Z Skowronska, MD</last_name>
    <phone>48225021144</phone>
    <email>marta.z.kozlowska@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Piotr Pruszczyk, Prof.</last_name>
    <phone>48225021144</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine &amp; Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Z Skowronska, MD</last_name>
      <phone>225021625</phone>
      <email>marta.z.kozlowska@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Piotr Pruszczyk, Prof.</last_name>
      <phone>225021144</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Marta Skowronska</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

